Stephens Inc. AR Buys 1,869 Shares of Thermo Fisher Scientific Inc. $TMO

Posted by Brian Himes on Jul 7th, 2026

Stephens Inc. AR increased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 8.6% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,680 shares of the medical research company’s stock after purchasing an additional 1,869 shares during the quarter. Stephens Inc. AR’s holdings in Thermo Fisher Scientific were worth $11,639,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Steigerwald Gordon & Koch Inc. increased its holdings in shares of Thermo Fisher Scientific by 17.6% during the first quarter. Steigerwald Gordon & Koch Inc. now owns 414 shares of the medical research company’s stock worth $204,000 after buying an additional 62 shares in the last quarter. GM Advisory Group LLC grew its position in Thermo Fisher Scientific by 12.3% during the 1st quarter. GM Advisory Group LLC now owns 3,208 shares of the medical research company’s stock worth $1,577,000 after acquiring an additional 351 shares during the last quarter. Praxis Investment Management Inc. increased its holdings in Thermo Fisher Scientific by 5.0% in the 1st quarter. Praxis Investment Management Inc. now owns 17,310 shares of the medical research company’s stock worth $8,508,000 after purchasing an additional 821 shares in the last quarter. Beacon Financial Advisory LLC raised its position in Thermo Fisher Scientific by 29.2% in the first quarter. Beacon Financial Advisory LLC now owns 513 shares of the medical research company’s stock valued at $252,000 after purchasing an additional 116 shares during the last quarter. Finally, Evolution Wealth Management Inc. boosted its stake in shares of Thermo Fisher Scientific by 175.0% during the first quarter. Evolution Wealth Management Inc. now owns 99 shares of the medical research company’s stock valued at $49,000 after purchasing an additional 63 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analyst Ratings Changes

TMO has been the subject of several recent research reports. Weiss Ratings downgraded Thermo Fisher Scientific from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, June 29th. Wolfe Research initiated coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $535.00 price objective on the stock. Sanford C. Bernstein began coverage on Thermo Fisher Scientific in a report on Friday, June 26th. They issued a “market perform” rating and a $520.00 price objective for the company. HSBC downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating and cut their target price for the stock from $670.00 to $540.00 in a report on Wednesday, June 3rd. Finally, Piper Sandler assumed coverage on Thermo Fisher Scientific in a research note on Thursday, June 11th. They issued a “neutral” rating and a $510.00 price target for the company. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $601.61.

Get Our Latest Research Report on TMO

Thermo Fisher Scientific Trading Up 0.2%

Shares of NYSE:TMO traded up $1.28 during midday trading on Tuesday, reaching $518.88. The company’s stock had a trading volume of 212,148 shares, compared to its average volume of 2,337,540. Thermo Fisher Scientific Inc. has a fifty-two week low of $403.36 and a fifty-two week high of $643.99. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53. The firm has a 50 day moving average price of $473.17 and a two-hundred day moving average price of $517.74. The firm has a market capitalization of $192.83 billion, a price-to-earnings ratio of 28.52, a PEG ratio of 2.32 and a beta of 0.87.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last released its earnings results on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, topping the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The business had revenue of $11.01 billion during the quarter, compared to analysts’ expectations of $10.86 billion. During the same quarter last year, the firm posted $5.15 earnings per share. The firm’s revenue was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, analysts forecast that Thermo Fisher Scientific Inc. will post 24.84 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Monday, June 15th will be given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Monday, June 15th. Thermo Fisher Scientific’s payout ratio is presently 10.34%.

Insider Buying and Selling

In other news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the transaction, the chief operating officer owned 25,051 shares in the company, valued at approximately $11,590,095.66. This represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.33% of the company’s stock.

About Thermo Fisher Scientific

(Free Report)

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.